Original Publication Date: 1 March, 2016
Publication / Source: Future Oncology
Authors: Pedro Nazareth Aguiar Jr, Thiago Pimentel Muniz, Raelson Rodrigues Miranda et al
In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use.